๐”– Bobbio Scriptorium
โœฆ   LIBER   โœฆ

Transient benefit of amantadine in Parkinson's disease: The facts about the myth

โœ Scribed by Stewart A. Factor; Eric S. Molho

Book ID
102681632
Publisher
John Wiley and Sons
Year
1999
Tongue
English
Weight
592 KB
Volume
14
Category
Article
ISSN
0885-3185

No coin nor oath required. For personal study only.

๐Ÿ“œ SIMILAR VOLUMES

Myths and facts about electricity in the
Myths and facts about electricity in the U.S. South
โœ Marilyn A. Brown; Etan Gumerman; Xiaojing Sun; Kenneth Sercy; Gyungwon Kim ๐Ÿ“‚ Article ๐Ÿ“… 2012 ๐Ÿ› Elsevier Science ๐ŸŒ English โš– 1003 KB
Association between amantadine and the o
Association between amantadine and the onset of dementia in Parkinson's disease
โœ Rivka Inzelberg; Ubaldo Bonuccelli; Edna Schechtman; Ala Miniowich; Rosa Strugat ๐Ÿ“‚ Article ๐Ÿ“… 2006 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 64 KB ๐Ÿ‘ 1 views

## Abstract The objective of this study is to compare the occurrence of dementia among Parkinson's disease (PD) patients treated with amantadine (AM group) with those never exposed to it (NoAM group). PD dementia shares neuroanatomical and biochemical similarities with Alzheimer's disease (AD). Mem